Screening methods for high-risk anal cancer patients
Official title: Screening Strategies Among High-risk Populations for Anal Cancer
Run by Emory University · NCT06628570 · Data updated 2026-11-12
This study is testing new ways to screen for early signs of anal cancer in high-risk people, especially those living with HIV, to help improve their health outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Emory University Academic / other |
| Locations | 4 sites (Miami, Florida and 3 other locations) |
| Status | Recruiting |
| Started | December 16, 2024 |
| Main results expected | September 30, 2027 |
| Study ends | August 31, 2028 |
| Registry record updated | August 26, 2026 |
| Trial ID | NCT06628570 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include Black or Latinx individuals aged 30 and older, specifically males who have sex with men (MSM) and females with a history of high-grade lower genital tract neoplasia.
✕Probably not a fit
Patients who have been treated for aHSIL within the last 6 months, those with a history of anal cancer, and pregnant women may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research aims to evaluate new screening techniques for anal high-grade squamous intraepithelial lesions (aHSIL), a precursor to anal cancer, particularly among minorities at high risk. The study focuses on individuals living with HIV, as they face a higher incidence of anal cancer. Participants will complete self-reported questionnaires and provide biosamples for analysis, which will help identify social determinants and biological factors associated with aHSIL. The findings are expected to inform better screening strategies and reduce health disparities in anal cancer outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved screening strategies that significantly reduce the incidence of anal cancer among high-risk populations.
How similar studies have gone: Other studies have shown success in screening approaches for HPV-related cancers, but this specific focus on high-risk minorities is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 30-80 years of age * Individuals with chronic impaired immune status * History of lower genital tract neoplasia (LGTN), Zubrod Performance Status of 0-2 Exclusion Criteria: * Patients treated for aHSIL less than 6 months before screening * History of anal cancer and pregnant women.
Where it's running
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States Recruiting -
University of Miami School of Medicine at Jackson Memorial Hospital (JMH)
Miami, Florida, United States Recruiting -
Grady Memorial Hospital
Atlanta, Georgia, United States Recruiting -
The Ponce Center
Atlanta, Georgia, United States Recruiting
Study contacts
- Principal investigator: Lisa Flowers, MD, MPH — Emory University
- Study coordinator: Lisa Flowers, MD, MPH
- Email: lflowe2@emory.edu
- Phone: 404-251-8931
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.